InMed Pharmaceuticals Files 8-K Current Report

Ticker: INM · Form: 8-K · Filed: May 13, 2025 · CIK: 1728328

Inmed Pharmaceuticals INC. 8-K Filing Summary
FieldDetail
CompanyInmed Pharmaceuticals INC. (INM)
Form Type8-K
Filed DateMay 13, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: 8-K, current-report, sec-filing

TL;DR

InMed Pharma filed an 8-K, check for updates.

AI Summary

InMed Pharmaceuticals Inc. filed an 8-K on May 13, 2025, reporting an event on May 12, 2025. The filing indicates it is a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. The company is incorporated in British Columbia and its principal executive offices are located in Vancouver, Canada.

Why It Matters

This filing signifies a routine update or disclosure from InMed Pharmaceuticals Inc. to the SEC, which may contain important information for investors regarding company events.

Risk Assessment

Risk Level: low — This is a standard 8-K filing for a current report, not indicating any immediate financial distress or significant negative events.

Key Players & Entities

FAQ

What specific event triggered this 8-K filing?

The filing states it is a 'Current Report' pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, but the specific event is not detailed in the provided text.

When was the earliest event reported?

The earliest event reported was on May 12, 2025.

What is the company's principal executive office address?

The company's principal executive offices are located at Suite 1445 - 885 W. Georgia Street, Vancouver, B.C. Canada, V6C 3E8.

What is the company's telephone number?

The company's telephone number, including area code, is (604) 669-7207.

In which jurisdiction is InMed Pharmaceuticals Inc. incorporated?

InMed Pharmaceuticals Inc. is incorporated in British Columbia.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on May 13, 2025 regarding InMed Pharmaceuticals Inc. (INM).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing